This is the authors' abstract. We don't add key points for this paper.
Background and aims In our previous work, a total of 103 CD8 + T-cell epitopes restricted by 13 prevalent HLA-A allotypes in Northeast Asians were validated from the main proteins of hepatitis B virus (HBV). This study aims to further screen the T-cell epitopes restricted by 15 prevalent HLA-B and 14 prevalent HLA-C allotypes and establish a universal assay for counting reactive HBV-specific T cells in patients with chronic hepatitis B (CHB). Methods CD8 + T-cell epitopes were systematically screened through a combination of in silico prediction, ex vivo co-cultures of peptides with patient-derived peripheral blood mononuclear cells (PBMCs), and peptide competitive binding assays using HLA-B/C transfected cell lines. Results A total of 89 novel CD8 + T-cell epitopes were identified from four HBV main proteins using PBMCs from 250 CHB patients. Furthermore, 201 validated CD8 + T-cell epitope peptides restricted by the 13 HLA-A, 15 HLA-B, and 14 HLA-C allotypes were integrated to construct a broad-spectrum epitope peptide library, and by which the ELISpot assay was established followed by clinical testing for 81 CHB patients. The counts of reactive HBV-specific T cells and T cells reactive to each HBV protein (HBsAg-, HBpol-, HBx-, or HBeAg-) in PBMCs showed a negative correlation with serum HBsAg levels and no correlation with HBeAg or ALT levels. NUCs/IFN-α combination elicited significantly more reactive HBV-specific T cells (including those targeting HBsAg, HBpol, HBx, or HBeAg) than NUCs or IFN-α monotherapy. Conclusions The proposed method holds great potential for facilitating routine evaluation of HBV-specific CD8 + T cell reactivity in CHB patients.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: